

IN THE SPECIFICATION

Please remove the word “DESCRIPTION” after the title on the first page of the application.

Please insert the following text on page 1 of the application between the title and the section entitled “TECHNICAL FIELD OF THE INVENTION”:

PRIORITY CLAIM TO RELATED PATENT APPLICATIONS

This patent application claims priority (as a U.S. national phase application filed under 35 U.S.C. §371) to International Patent Application No. PCT/ES03/00394 (filed July 29, 2003), which, in turn, claims priority to Spanish Patent Application No. P 200201811 (filed July 31, 2002). The entire content of each of these priority patent applications is incorporated by reference into this patent application.

Please insert the following text after the last sentence of the “BACKGROUND OF THE INVENTION” section on page 3 of the application:

No admission is made that any reference (or a portion of any reference) discussed above is prior art.

Please insert the following text after page 1 and before page 3 of the specification.
thereof being both presynaptic and postsynaptic, are the target of a group of anxiolytic drugs and perhaps they are also involved in the actions of specific anti-depressant drugs.

In ES 2052829 substituted aminoethyl tetralins and analogous heterocyclics are disclosed as selective agonists of the 5-HT_{1A} subtype serotonergic receptors. One of the products disclosed in said document, BAYx3702, has shown experimentally, both *in vitro* (Suchanek et al., 1998; Ahlemeyer et al., 1999) and *in vivo* (Schaper et al., 2000; Torup et al., 2000; Kline et al., 2001), its neuroprotective effect due to its agonist action on the 5-HT_{1A} receptor.

Spanish patent application no. 200102113, of the same authors of the present invention, discloses a series of compounds that behave as pure 5-HT_{1A} receptor agonists

although with only moderate potency, wherein neuroprotective action of this series of compounds could only be demonstrated using primary rat neuronal cultures.

The neuroprotective effect of the 5-HT_{1A} receptor agonists may be due to different mechanisms amongst which the hyperpolarization in the activation of K⁺ channels, glutamate release inhibition (Matsuyama et al., 1996; Mauler et al., 2001) and the increase in BDNF neurotrophin expression (Galter et al. 2000) are highlighted.

The aforementioned data enables prediction of a new application for the compounds capable of activating the 5-HT_{1A} receptors, namely, their use in the treatment of cerebral damage associated with ischemia/hypoxia processes or traumatic incidents. Therefore, it is of great interest to have new agonist compounds of serotonergic 5-HT_{1A} receptors which have neuroprotective effects and which can provide efficient treatment against cerebral damage associated with ischemia/hypoxia processes or cranium-brain traumatic

On page 5 please replace the 3rd full paragraph with the following text.

Unless otherwise indicated, the alkynyl groups referred to in the present invention are linear (e.g. 2-butyne).